SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (“HDC”) (OTCBB: HDVY) today announced that HDC’s new gene-based molecular diagnostic test for prostate cancer which has now successfully completed its Phase III double-blind clinical trial and is now ready for commercialization, will be presented at the upcoming Biomarker Discovery Europe 2008 conference in Dublin, Ireland on October 2-3. The new prostate cancer test will be performed at Clarient’s Clinical Laboratory in Aliso Viejo, CA. HDC will receive 30% royalty on each test performed.
